Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The science behind both is real
Withdraw the needle, apply pressure, and re-inject at a slightly different angle
While Pharmaoffer aims to keep information up to date, it does not guarantee the accuracy, completeness, or current validity of any supplier data
The LEADER trial enrolled patients with T2DM and high cardiovascular risk, defined as established CVD (81%) or age 60 years with at least one risk factor, and showed that liraglutide significantly reduced the incidence of 3-point major adverse cardiovascular events (MACE) (i.e., CV death, non-fatal myocardial infarction, non-fatal stroke) by 13% compared to placebo (HR 0.87
US$ 21.50
US$ 26.01
US$ 23.27
